Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats

Biochemical Pharmacology

Volumn 77, Issue 6, 2009, Pages 1053-1063

  Rivera, Leonor ^a   Morón, Rocío ^a   Zarzuelo, Antonio ^a   Galisteo, Milagros ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AMPK activation; Inflammatory status; Metabolic syndrome; Obese Zucker rats; Resveratrol

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE PHOSPHATE; ADIPONECTIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; RESVERATROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; HORMONE BLOOD LEVEL; INFLAMMATION; LONG TERM CARE; MALE; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER RAT;

ADIPOSE TISSUE; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; OBESITY; RANDOM ALLOCATION; RATS; RATS, ZUCKER; STILBENES;

EID: 60949087943     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.027     Document Type: Article

References (51)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1998) 1595-1607
2. Reaven G. Pathophysiology of insulin resistance in human disease. Physiol Rev 75 (1995) 473-486
3. Lebovitz H.E. Insulin resistance; definition and consequences. Exp Clin Endocrinol Diabetes 109 (2001) S135-S148
4. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 (2007) 328-341
5. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144 (2003) 5179-5183
6. 2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem 270 (1995) 27186-27191
7. Hardie D.G., and Pan D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 30 (2002) 1064-1070
8. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
9. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Müller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002) 339-343
10. Ruderman N., and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3 (2004) 340-351
11. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55 (2006) 2180-2191
12. Collins Q.F., Liu H.Y., Pi J., Liu Z., Quon M.J., and Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J Biol Chem 282 (2007) 30143-30149
13. Kim E.J., Jung S.N., Son K.H., Kim S.R., Ha T.Y., Park M.G., et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol 72 (2007) 62-72
14. Rivera L., Moron R., Sánchez M., Zarzuelo A., and Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 16 (2008) 2081-2087
15. Orallo F., Alvarez E., Camiña M., Leiro J.M., Gómez E., and Fernández P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 61 (2002) 294-302
16. Wolter F., Ulrich S., and Stein J. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: key role of polyamines?. J Nutr 134 (2004) 3219-3222
17. Leiro J., Alvarez E., Arranz J.A., Laguna R., Uriarte E., and Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 75 (2004) 1156-1165
18. Bhat K.P.L., Kosmeder II J.W., and Pezzuto J.M. Biological effects of resveratrol. Antioxid Redox Signal 3 (2001) 1041-1064
19. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106 (2002) 1652-1658
20. Bradamante S., Barenghi L., and Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22 (2004) 169-188
21. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
22. Reznick R.M., Zong H., Li J., Morino K., Moore I.K., Yu H.J., et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 5 (2007) 151-156
23. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450 (2007) 712-716
24. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283 (2008) 20015-20026
25. Park C.E., Kim M.J., Lee J.H., Min B.I., Bae H., Choe W., et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39 (2007) 222-229
26. Dasgupta B., and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104 (2007) 7217-7222
27. Zucker L.M., and Antoniades H.N. Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology 90 (1972) 1320-1333
28. Kurtz T.W., Morris R.C., and Pershadsingh H.A. The fatty Zucker rat as a genetic model of obesity and hypertension. Hypertension 13 (1989) 896-901
29. Iida M., Murakami T., Ishida K., Mizuno A., Kuwajima M., and Shima K. Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun 222 (1996) 19-26
30. Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J., et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13 (1996) 18-19
31. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., and Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
32. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Med Sci 37 (1959) 911-917
33. Duarte J., Jimenez R., O'Valle F., Galisteo M., Pérez-Palencia R., Vargas F., et al. Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20 (2002) 1843-1854
34. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
35. Buhl E.S., Jessen N., Pold R., Ledet T., Flyvbjerg A., Pedersen S.B., et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51 (2002) 2199-2206
36. Winder W.W., Holmes B.F., Rubink D.S., Jensen E.B., Chen M., and Holloszy J.O. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88 (2000) 2219-2226
37. Raz I., Eldor R., Cernea S., and Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 21 (2005) 3-14
38. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111 (2003) 246-250
39. Pavlic M., Valéro R., Duez H., Xiao C., Szeto L., Patterson B.W., et al. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol 28 (2008) 1660-1665
40. Yu X., McCorkle S., Wang M., Lee Y., Li J., Saha A.K., et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 47 (2004) 2012-2021
41. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
42. Galisteo M., Sanchez M., Vera R., Gonzalez M., Anguera A., Duarte J., et al. A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats. J Nutr 135 (2005) 2399-2404
43. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
44. Esposito K., Nappo F., Giugliano F., Di Palo C., Ciotola M., Barbieri M., et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 78 (2003) 1135-1140
45. Duplain H., Burcelin R., Sartori C., Cook S., Egli M., Lepori M., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104 (2001) 342-345
46. Valerio A., Cardile A., Cozzi V., Bracale R., Tedesco L., Pisconti A., et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 116 (2006) 2791-2798
47. Perreault M., and Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7 (2001) 1138-1143
48. Levine Y.C., Li G.K., and Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK - Rac1 - Akt - endothelial nitric-oxide synthase pathway. J Biol Chem 282 (2007) 20351-20364
49. Liu Z., Song Y., Zhang X., Liu Z., Zhang W., Mao W., et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 32 (2005) 1049-1054
50. Du X., Edelstein D., Obici S., Higham N., Zou M.H., and Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 116 (2006) 1071-1080
51. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 (1997) 1230-1239